Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Mustang Bio Inc. (MBIO:NASDAQ), powered by AI.
Mustang Bio Inc. is currently trading at $0.70. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Mustang Bio Inc. on Alpha Lenz.
Mustang Bio Inc.'s P/E ratio is -1.8.
“Mustang Bio Inc. trades at a P/E of -1.8 (undervalued) with modest ROE of -67.9%.”
Ask for details →Mustang Bio Inc. is a biotechnology company specializing in the development and commercialization of innovative and targeted therapies in the field of oncology. Its primary function is to advance the treatment of various cancers and genetic diseases through proprietary cell and gene therapies. Mustang Bio focuses on leveraging its scientific expertise to create therapies that specifically target cancer cells, hence improving treatment outcomes while minimizing side effects. The company’s research and development efforts have led to a robust pipeline, particularly concentrating on CAR-T cell therapies and gene therapies. Operating within the dynamic and rapidly evolving biotechnology industry, Mustang Bio plays a crucial role in addressing unmet medical needs, bringing transformative therapies from the laboratory to the clinic. By collaborating with academic institutions and a network of research partners, Mustang Bio enhances its capabilities in developing next-generation therapies. The company's contributions to the biotech sector underline its importance in bringing cutting-edge medical solutions to market, potentially transforming patient care and offering new hope in the treatment of life-threatening diseases.
“Mustang Bio Inc. trades at a P/E of -1.8 (undervalued) with modest ROE of -67.9%.”
Ask for details →Mustang Bio Inc. (ticker: MBIO) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 6 employees. Market cap is $3M.
The current price is $0.703 with a P/E ratio of -1.8x and P/B of 0.36x.
ROE is -67.93%.